From the Food and Drug Administration.
作者信息
Nightingale S L
出版信息
JAMA. 1998 Sep 9;280(10):872. doi: 10.1001/jama.280.10.872-jfd80008-2-1.
Abstract
摘要
相似文献
1
From the Food and Drug Administration.
JAMA. 1998 Sep 9;280(10):872. doi: 10.1001/jama.280.10.872-jfd80008-2-1.
2
Preparing for thalidomide's comeback.为沙利度胺的复出做准备。
Ann Intern Med. 1997 Nov 15;127(10):951-2. doi: 10.7326/0003-4819-127-10-199711150-00023.
3
Does thalidomide have a role in leprosy?沙利度胺在麻风病治疗中是否有作用？
Lancet. 2004 Jun 5;363(9424):1911. doi: 10.1016/S0140-6736(04)16376-9.
4
[Treatment of erythema nodosum leprosum using thalidomide].[使用沙利度胺治疗麻风结节性红斑]
Acta Leprol. 1983 Jan-Mar;1(1):41-50.
5
No role for thalidomide in the treatment of leprosy.沙利度胺在麻风病治疗中无作用。
J Infect Dis. 2006 Jun 15;193(12):1743-4; author reply 1744-5. doi: 10.1086/504295.
6
Thalidomide: the past, present, and future.沙利度胺：过去、现在与未来。
J Assoc Nurses AIDS Care. 1999 Mar-Apr;10(2):82-4. doi: 10.1016/S1055-3290(06)60303-8.
7
The schizophrenic career of a "monster drug".
Pediatrics. 2003 Mar;111(3):712. doi: 10.1542/peds.111.3.712.
8
Thalidomide in the treatment of leprosy.沙利度胺治疗麻风病。
Microbes Infect. 2002 Sep;4(11):1193-202. doi: 10.1016/s1286-4579(02)01645-3.
9
[Thalidomide used by patients with erythema nodosum leprosum].[沙利度胺用于麻风结节性红斑患者]
Rev Soc Bras Med Trop. 2010 Mar-Apr;43(2):201-4. doi: 10.1590/s0037-86822010000200019.
10
Clinicopathologic challenge.
Int J Dermatol. 2007 Apr;46(4):348-9. doi: 10.1111/j.1365-4632.2007.03203.x.
引用本文的文献
1
Revisiting potential value of antitumor drugs in the treatment of COVID-19.重新审视抗肿瘤药物在治疗新型冠状病毒肺炎中的潜在价值。
Cell Biosci. 2022 Oct 1;12(1):165. doi: 10.1186/s13578-022-00899-z.
2
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.在非人灵长类动物中沙利度胺和来那度胺的血浆和脑脊液药代动力学。
Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.
Zotero 插件